A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial

被引：0
|
作者：
Di Giacomo, A. M. [1 ]
Ascierto, P. A. [2 ]
Pittiglio, E. [1 ]
Queirolo, P. [3 ]
Pilla, L. [4 ]
Ridolfi, R. [5 ]
Santinami, M. [6 ]
Testori, A. [7 ]
Parmiani, G. [4 ]
Maio, M. [1 ]
机构：
[1] Univ Hosp Siena, Siena, Italy
[2] NCI, Naples, Italy
[3] Natl Inst Canc Res, Genoa, Italy
[4] San Raffaele Sci & Univ Inst, Milan, Italy
[5] Sci Inst Romagna, Immunotherapy & Somat Cell Therapy Unit, Meldola, Italy
[6] Natl Canc Inst, I-20133 Milan, Italy
[7] European Inst Oncol, Melanoma & Muscle Cutaneous Sarcoma Div, Milan, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S653 / S654
页数：2
相关论文
共 50 条
  • [1] A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.
    Di Giacomo, A. M.
    Ascierto, P. A.
    Fonsatti, E.
    Pittiglio, E.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Parmiani, G.
    Maio, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases
    Maio, Michele
    Testori, Alessandro
    Ascierto, Paolo Antonio
    Ridolfi, Ruggero
    Santinami, Mario
    Pilla, Lorenzo
    Queirolo, Paola
    Grosso, Marco
    Simeone, Ester
    Vittoria, Stefania
    Nicoletti, Luisa
    Rivoltini, Licia
    Ferrucci, Pier Francesco
    Parmiani, Giorgio
    Di Giacomo, Anna Maria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
    Di Giacomo, Anna Maria
    Ascierto, Paolo A.
    Pilla, Lorenzo
    Santinami, Mario
    Ferrucci, Pier Francesco
    Giannarelli, Diana
    Marasco, Antonella
    Rivoltini, Licia
    Simeone, Ester
    Nicoletti, Stefania V. L.
    Fonsatti, Ester
    Annesi, Diego
    Queirolo, Paola
    Testori, Alessandro
    Ridolfi, Ruggero
    Parmiani, Giorgio
    Maio, Michele
    [J]. LANCET ONCOLOGY, 2012, 13 (09): : 879 - 886
  • [4] Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
    Maccalli, Cristina
    Giannarelli, Diana
    Capocefalo, Filippo
    Pilla, Lorenzo
    Fonsatti, Ester
    Di Giacomo, Anna Maria
    Parmiani, Giorgio
    Maio, Michele
    [J]. ONCOIMMUNOLOGY, 2016, 5 (02):
  • [5] Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.
    Di Giacomo, Anna Maria
    Ascierto, Paolo Antonio
    Pilla, Lorenzo
    Ridolfi, Ruggero
    Santinami, Mario
    Testori, Alessandro
    Queirolo, Paola
    Simeone, Ester
    Guidoboni, Massimo
    Del Vecchio, Michele
    Ferrucci, Pier Francesco
    Marasco, Antonella
    Fonsatti, Ester
    Annesi, Diego
    Giannarelli, Diana
    Parmiani, Giorgio
    Maio, Michele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.
    Di Giacomo, Anna Maria
    Annesi, Diego
    Ascierto, Paolo Antonio
    Calabro, Luana
    Chiarion-Sileni, Vanna
    Danielli, Riccardo
    Del Vecchio, Michele
    Ferraresi, Virginia
    Ferrucci, Pier Francesco
    Fonsatti, Ester
    Guida, Michele
    Giannarelli, Diana
    Guidoboni, Massimo
    Mandala, Mario
    Quaglino, Pietro
    Queirolo, Paola
    Maccalli, Cristina
    Parmiani, Giorgio
    Maio, Michele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
    Di Giacomo, A. M.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Ferrucci, P. F.
    Guida, M.
    Quaglino, P.
    Guidoboni, M.
    Marchetti, P.
    Cutaia, O.
    Amato, G.
    Gambale, E.
    Calabro, L.
    Valente, M.
    Danielli, R.
    Giannarelli, D.
    Mandala, M.
    Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S734 - S734
  • [8] A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with melanoma with brain metastasis: The NIBIT-M2 study
    Di Giacomo, A. M.
    Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 5 - 5
  • [9] The Italian Network for Tumor Biotherapy (NIBIT)-M1 study: 2-years survival update for metastatic melanoma patients treated with ipilimumab in combination with fotemustine
    Di Giacomo, A. M.
    Ascierto, P. A.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Giannarelli, D.
    Parmiani, G.
    Maio, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [10] PHASE-II TRIAL OF FOTEMUSTINE IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA
    FALKSON, CI
    FALKSON, G
    FALKSON, HC
    [J]. INVESTIGATIONAL NEW DRUGS, 1994, 12 (03) : 251 - 254
12345